Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
adult vaccines
Biotech
HHS delivers stop work order to Atlanta biotech, pulls funding
In June 2024, the government granted GeoVax $24.3 million to run a 10,000-participant phase 2b study for its next-gen COVID vaccine.
Gabrielle Masson
Apr 16, 2025 11:02am
VC firm fights to end Dynavax's 'empire-building' strategy
Feb 19, 2025 2:22pm
GSK, Merck and Pfizer in Ab&B's sights as biotech files for IPO
Jan 23, 2025 8:01am
JPM25, Day 2: Pharma should 'run towards' vaccine conversations
Jan 14, 2025 11:30am
ILiAD's pertussis shot joins Trojan horse of childhood vaccines
May 28, 2024 10:41am
FDA delays decision on Moderna's RSV shot until the end of May
May 10, 2024 10:30am
